# Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

> **NCT02900716** · PHASE1 · COMPLETED · sponsor: **Zhejiang DTRM Biopharma** · enrollment: 48 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- B-Cell Lymphoma

## Interventions

- **DRUG:** DTRMWXHS-12
- **DRUG:** DTRM-505
- **DRUG:** DTRM-555

## Key facts

- **NCT ID:** NCT02900716
- **Lead sponsor:** Zhejiang DTRM Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2020-11-23
- **Final completion:** 2020-11-23
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02900716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02900716, "Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02900716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*